Results 71 to 80 of about 11,438 (231)

A New Problem of Adolescents: “Bonsai”

Journal of Pediatric Research, 2017
Synthetic cannabinoids have been increasingly used by adolescents in the recent years. In our country, synthetic cannabinoids are known as “bonsai”. They may cause neuropsychiatric effects such as psychosis, agitation, ataxia, convulsion, hallucinations,
Özlem Gül, Dolunay Gürses, Emine Özdemir, Ferhat Yıldız   +3 more
doaj   +1 more source

Weighted prevalence of biochemically verified substance use in healthy adolescents across the USA

Addiction, EarlyView.
Abstract Background and aims Adolescent substance use is a significant public health concern, though the scope of the problem is difficult to ascertain given reliance on self‐reported substance use information. Recent, large cohort studies in adolescents and young adults suggest underreporting of substance use.
Natasha E. Wade, Yajuan Si, Susan F. Tapert, Janosch Linkersdörfer, Krista M. Lisdahl, Hailley R. Moore, Laila Tally, Biplabendu Das, Marilyn A. Huestis, Alexander L. Wallace, Ryan M. Sullivan, Veronica Szpak, Le Zhang, Laura Ziemer, Wesley K. Thompson   +14 more
wiley   +1 more source

A Case of Cannabinoid Hyperemesis Syndrome Caused by Synthetic Cannabinoids

The Journal of Emergency Medicine, 2013
Cannabinoid hyperemesis syndrome (CHS) was initially described in 2004 and remains an under-recognized clinical entity that occurs in chronic heavy marijuana smokers.We describe the first report of CHS in an abuser of synthetic cannabinoids. CHS is thought to be caused by over-stimulation of the cannabinoid 1 receptor.
unknown ( host institution ), Hopkins, Christopher Y. ( author )   +1 more
openaire   +3 more sources

Toxicokinetic modelling of the synthetic cannabinoid 5F‐MDMB‐P7AICA and its main metabolite in pigs following pulmonary administration

British Journal of Clinical Pharmacology, EarlyView.
Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr, Christiane Dings, Omar Zaher, Frederike Nordmeier, Nadja Walle, Matthias W. Laschke, Michael D. Menger, Peter H. Schmidt, Markus R. Meyer, Thorsten Lehr, Nadine Schaefer   +10 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Covalent fluorescent probes for 2‐arachidonoylglycerol metabolic pathways

British Journal of Pharmacology, EarlyView.
Abstract Covalent fluorescent probes have emerged as versatile chemical tools to visualise active enzymes in complex biological systems. When tailored for specific applications, ranging from activity‐based protein profiling for drug development to high spatiotemporal resolution imaging of enzymatic activities, these probes provide unique insights into ...
Nick D. F. Puijmbroeck, Mario van der Stelt   +1 more
wiley   +1 more source

Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Opioid use disorder, particularly involving fentanyl, poses major challenges due to high relapse rates and limited effectiveness of pharmacotherapies. The kynurenine pathway has emerged as a target for addiction treatment through its modulation of glutamatergic and dopaminergic neurotransmission.
Carlos Núñez‐de la Calle, Lluna Careaga, Stefanie Malan‐Müller, Álvaro del Río‐García, Yaiza Trueba, Leticia Gil de Biedma‐Elduayen, Nuria Morales‐Puerto, Rebeca Vidal, Åsa Wiman, Sophie Erhardt, María Dolores Gutiérrez‐López, Esther O'Shea, María Isabel Colado   +12 more
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Cryptogenic stroke in young patients and cannabis use: case presentation and literature review

Neurologijos seminarai, 2019
Approximately 10% of ischemic strokes occur in people under the age of 50 – this is called early on set or stroke in young adults. In this patient population, there is an especially high number of cryptogenic strokes, where etiology is not identified or
A. Atkočiūnas , A. Jasionis , G. Lengvenis , R. Badaras , K. Ryliškienė   +4 more
doaj   +1 more source